Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Tonix Pharma ( (TNXP) ) is now available.
On June 12, 2025, Tonix Pharmaceuticals appointed James Hunter to its Board of Directors. Mr. Hunter, who previously served as the company’s Executive Vice President of Commercial Operations and has extensive experience in commercial, sales, and marketing, was deemed not independent under NASDAQ standards. His appointment reflects the company’s strategic focus on leveraging his expertise for future growth.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score is buoyed by positive technical indicators and promising corporate events, suggesting potential growth. However, the lack of profitability and reliance on external funding present significant risks. The company’s strong market momentum and strategic advancements provide a solid foundation for potential future success, though investors must be mindful of financial sustainability challenges.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products. The company is engaged in product development, clinical trials, and regulatory processes, aiming to enhance its market position and explore growth opportunities.
Average Trading Volume: 1,225,717
Technical Sentiment Signal: Sell
Current Market Cap: $276.2M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.